Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
This article was originally published in The Pink Sheet Daily
The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.
You may also be interested in...
FDA tells Genzyme a consent decree to ensure GMP compliance is likely, but firm notes sanctions would be related only to Allston Landing facility.
Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.
Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.